התחייבויות שוטפות של החברה: Gain Therapeutics Inc. (GANX)

Gain Therapeutics, Inc. (GANX) utilizes IT solutions in the US and Switzerland to combat neurodegeneration, as evidenced by the Change in Current Liabilities, where the metric reached 0.00. Business growth relies on the expansion of the SEE-Tx system to capture the CNS market. High patient demand and a lack of competition in the protein restoration segment create powerful potential for the future client base.

This indicator captures total liabilities with a maturity of up to one year, allowing for an assessment of cash gap risks and the pressure of interest payments on liquidity. By analyzing the short-term debt of Gain Therapeutics, Inc. (GANX), an investor can determine the company's ability to fund the hiring of specialized regulatory experts and the retention of key scientific staff without the emergency procurement of expensive borrowed capital.